Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 31, 2015
- Accepted in final form April 20, 2015
- First Published June 18, 2015.
Author Disclosures
- Joanna Kitley, DPhil,
- Mark Woodhall, PhD,
- M. Isabel Leite, DPhil,
- Jackie Palace, MD,
- Angela Vincent, FRS and
- Patrick Waters, PhD
- Joanna Kitley, DPhil,
NONE
NONE
Dr Kitley has received speaking honoraria from Novartis and Terumo BCT and support for scientific meetings from Teva, Novartis and Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr Kitley was supported by the NHS National Specialised Commissioning Group for Neuromyelitis Optica from Sep 2010 to Sep 2013.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Woodhall, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- M. Isabel Leite, DPhil,
NONE
NONE
Dr Leite is supported by NHS National Specialised Commissioning Group for Neuromyelitis optica, UK, and by NIHR Oxford Biomedical Research Centre, and has received speaking honoraria from Biogen Idec and travel and educational grants from Biogen Idec and UK.
Neuromuscular Disorders, editorial board member, from January 2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jackie Palace, MD,
UK advisory board participant: 1) Merck Serono 2) Bayer Schering Pharma 3) Biogen Idec 4) Teva Pharmaceutical Industries Ltd. 5) Novartis Pharmaceuticals UK Ltd. 6) Sanofi-Aventis 7) Alexion
NONE
Support for attending ECTRIMS Merck Serono Novartis and Biogen idec Talks at scientific meetings (majority have CME) Bayer schering, Biogen Idec, Merk Serono, Medimmune
NONE
(1) ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.
NONE
NONE
In addition to advisory committees, consultant for: Ono Pharmaceuticals Ltd. Chugai Pharma Ltd. CI Consulting Biogen Idec GlaxoSmithKline
NONE
NONE
NONE
Donations to support local service development and research, none relevant to the current work:Bayer Schering Merke Serono Novartis
Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service
NONE
MS Society UK Guthy Jackson Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Vincent, FRS and
NONE
NONE
Occasional small honoraria, travel and speaker honoraria from Baxter International Inc and Biogen Inc
Advisory Editorial Board Neurology; Associate Editor for Brain ended 2013
Hold patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG.
Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010).
NONE
Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Ended 2014.
Scientific conference expenses only
NONE
NONE
NONE
NONE
NIHR general support for antibody work
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Waters, PhD
NONE
NONE
Speaker honoraria from Biogen Idec Japan and Euroimmun AG.
Frontiers in molecular innate immunity, Review editor
Assays for the detection of antibodies to lgi1, Caspr2, Tag-1 and GABAAR.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Patents for CASPR2, LGI1, TAG-1 and GABAAR.
NONE
NONE
NONE
- From the Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
- Correspondence to Prof. Vincent: angela.vincent{at}ndcn.ox.ac.uk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Articles
AQP4 antibody–positive Thai casesClinical features and diagnostic problemsS. Siritho, I. Nakashima, T. Takahashi et al.Neurology, August 03, 2011 -
Articles
A population-based study of neuromyelitis optica in CaucasiansN. Asgari, S.T. Lillevang, H.P.B. Skejoe et al.Neurology, May 02, 2011